Inside the Tulane Cancer Center
June 2004 Newsletter
Headlines in this Issue
Tribute to Oncology Nurses
ACCTION Clinical Research Network
Groundbreaking for the Louisiana Cancer Research Center
Meet Melanie Ehrlich, Tulane Cancer Research Pioneer
Thanking the Benefactors who Support Our Mission
Research Day Winners 2004
A Message from the Director
Accolades: Faculty honors and awards
Index to all archived issues
Index to archived articles by topic
Editorial Staff & Contacts



Tribute to Oncology Nurses
Exceptional People Providing Exceptional Care
Nurses
Tulane Cancer Center nurses (from left):
Wanda Brooks, R.N., M.S.N.; Winifred Johnson, R.N., M.S.N.; Emi Ardoin, R.N.; Heidi Huber, R.N., B.S.N.; Darla Patrick, R.N.; Freida Hawley, R.N.; Karen Robinson, R.N.; and Dawn Morrison, R.N.
Many of them had toy nursing kits and perfected their skills early by wrapping family members' imaginary broken bones. Most of them grew up with an idealized image of nursing in their minds-the proper professional in the starched white uniform, the doctor's ever-vigilant and capable assistant, the compassionate soul whose call it was to help sick people feel better. "I wanted to be that person," said Emi Ardoin, R.N., a Tulane Cancer Center Comprehensive Clinic (TCCCC) infusion nurse with over 40 years of nursing experience. "I wanted to help people."

Ardoin's comments sum up the answers of just about all of the TCCCC nurses when asked what made them decide to go into nursing as a profession. Still others say nurses who had touched their lives in the past made them want to pursue this career. "I had a family member who had cancer," said Heidi Huber, R.N., B.S.N., "and the people we remember most helping us through it day to day were the nurses." Anna Hall, R.N., Radiation Oncology nurse, has a theory about why. "Patients look up to their doctors," said Hall. "They hold them in very high esteem. Sometimes, these same patients feel a little more comfortable with us, and so we're able to establish special relationships with them and their families." Wanda Brooks, R.N., M.S.N., clinical nurse specialist in the Office of Clinical Research, feels this closeness also develops from a dedication among Tulane Cancer Center's entire medical staff to treating the whole patient, not just his or her cancer. "Our patients are not defined by their cancers; they're people with diverse backgrounds and lives away from the Clinic. We have to be sensitive to that," said Brooks. "There are emotional considerations, economic issues, family dynamics, and religious questions -- all of these have to be taken into account if we're going to treat the whole person." She feels that nurses probably have the best vantage point for learning these special considerations and communicating them to the rest of the medical staff.

Most agree that oncologic nursing is different from general nursing, at times more difficult, but ultimately more rewarding. "Many people react negatively when you tell them that you are an oncology nurse," said Darla Patrick, R.N., "but helping people during one of the most stressful times in their lives can be very rewarding. Our patients are like family members to us." Nicole Candiff, R.N., B.S.N., Radiation Oncology nurse, has also experienced this closeness. "Oncology nurses are able to develop an intimacy that nurses typically don't reach with other types of patients," said Candiff. It's not difficult to understand why. Ardoin knows from experience that a cancer diagnosis brings with it a huge amount of anxiety. "In an instant, their lives are changed," she said. "It's important they never feel alone in their struggles. It's our job to care for them, counsel them, educate them. But sometimes, the most important thing we can do is to sit with them, listen to them, hold their hands, or even cry with them." Winifred Johnson, R.N., M.S.N., clinical research nurse, also acknowledges this special bond. "There's a spiritual reward that comes from working with cancer patients," said Johnson. "We're there to help them through the bad days, but we're also there to celebrate the good ones." Sharron Bannon, R.N., gets inspiration from her patients. "I look at our patients as heroes, and the opportunity to care for them is more than a job, it's a privilege." Kim Haley, R.N., B.S.N., agrees. "I learn so many things from my patients -- strength, courage, perseverance," said Haley. "How many people can say they see these qualities on a daily basis? I see them everyday in my patients."

Often, however, it's not just the patients the nurses find themselves assisting. "The family members of the patients, the caregivers, are also in need of information, resources and emotional support," said Denise Foxworth, R.N., B.S.N., clinical research nurse. This is especially true at the time of diagnosis. Oncology nurses play a vital role in educating the entire family, providing the information they will need not only to cope with a diagnosis of cancer, but also to understand their options, comply with a treatment plan, and support each other every step of the way. And so, an oncology nurse's day can be challenging. It's not your typical nine to five. Clinics can run late, beepers often go off after hours, and sharing so closely in the struggles of their patients can affect the nurses' lives both on and off the job. It doesn't just go away at the end of the day. How do they handle this? "We vent to each other, support each other, console each other," said Brooks. "I find strength in the success stories," said Freida Hawley, R.N., Bone Marrow Transplant coordinator. "I see the glimmer of hope in my patients' eyes that their treatments are going to work. It's wonderful to celebrate their success stories."

And what about that image of the perfect nurse they all grew up with? Well, they agree that it's not quite as idealistic as they thought when they were 10, but one perception hasn't changed. "Nursing is an admirable profession," said Johnson. "Being a nurse and being a blessing in someone's life brings blessing to mine." All of them say their unique perspective gives them a greater appreciation for life. "Watching patients fight their diseases makes you look at your own mortality," said Candiff. "It makes you value each healthy day a little more." The dedication of the TCCCC nursing staff does not go unnoticed by the physicians, the staff or the patients. Dawn Morrison, R.N., clinical manager, says it best: "Every day I watch the nurses here make a difference in someone's life. We often hear that it takes a special person to be a nurse. It takes an extraordinarily special person to be an oncology nurse. That's what we have here-truly special individuals-and I appreciate each one of them."
------------
ACCTION Plan for Clinical Research
Accessible Locations, Accessible Care
ACCTION, Tulane's Affiliated Community Clinical Trials Integrated Oncology Network, is an affiliation of nine community oncology practices throughout Louisiana, Mississippi, Alabama, and Florida that provides access to Tulane Cancer Center's 88 adult clinical trials to patients in their own communities. "Our system provides easy access to leading-edge care without sacrificing patient convenience," said Roy S. Weiner, M.D., director of the Tulane Cancer Center. Through ACCTION, instead of traveling to New Orleans, patients are able to continue seeing their community oncologists while participating in a clinical trial for the treatment or prevention of cancer. ACCTION overcomes the clinical trials access barrier by providing community physicians not previously associated with a research-based institution with the resources necessary and a model for performing clinical research. "We take a hands-on approach with the personnel at our affiliate sites," said Jurisich. "We make frequent visits, instructing them on how to set up a clinical research office within their practice and educating them on how to administer clinical trials." The community physicians are able to choose the trials they feel are appropriate for their patients and their community. Often, the Tulane physicians who are the principal investigators of many of these trials make site visits and provide educational seminars to the affiliate's staff.

Betty Jurisich, R.N., B.S.N., M.P.H.,O.C.N., C.C.R.P.
Director of Tulane's Office of Clinical Research

It's a win/win situation for the community physicians and their patients. Because patients don't have to leave home to participate in a clinical trial, they can continue to see the community oncologists they have already established relationships with, thus promoting continuity of care. And the community physicians can offer cutting-edge investigational treatment / prevention options not otherwise available within their communities. Greater access to and participation in clinical trials also benefits all of us by helping to advance science. "Clinical research is how we learn to better treat and prevent cancer," said Jurisich. "The greater the number of trial participants, the less time it takes to build a body of knowledge that is science-based. If we can positively impact the number of patients participating in clinical trials, we can perhaps shorten our timeline and take the next step toward our ultimate goal of finding a cure for cancer." Jurisich's team is doing their part. While only 4% of cancer patients participated in clinical trials nationwide in 2002, the Tulane Cancer Center boasted an 8% participation rate. Look for the ACCTION Network to expand in 2004. "We're hoping to add Lafayette and Monroe, Louisiana, to our list of affiliate sites some time later this year," said Jurisich.


------------
Louisiana Cancer Research Center Groundbreaking
A Celebration and a Prelude
Gov. Blanco On Wednesday, December 3, 2003, the normally quiet parking lot next to St. Joseph's Church on the corner of Tulane Avenue and S. Claiborne became a whirlwind of activity and excitement, as state legislators, members of city government, physicians, cancer survivors, media representatives and the academic leadership, faculty and staff from the LSU and Tulane University health sciences centers met for the ceremonial groundbreaking for the Louisiana Cancer Research Center. This shared 150,000-gross-square-foot facility will occupy this corner and will house the Louisiana Cancer Research Consortium's (LCRC) state-of-the-art equipment and laboratories, as well as the talented cancer researchers from Tulane and LSU who have already joined forces. The center will cost approximately $55 million and will take approximately 15 months to complete once construction begins.
Roy S. Weiner, M.D., welcomes Governor Kathleen Blanco to the Groundbreaking Ceremony.

The purpose of the ceremonial groundbreaking was to publicly thank the legislators, institutions, researchers, and private citizens who worked so hard to make the Consortium and the new Research Center a reality. "This is the next step toward our ultimate goal of providing the citizens of Louisiana with an NCI-Designated Cancer Center in their home state," said Roy S. Weiner, M.D., director of the Tulane Cancer Center. NCI designation for the Consortium will acknowledge the high-quality cancer research, education, and treatment that Tulane and LSU have been providing to Louisiana's citizens all along. "It will bring us to a new level in our fight against cancer," said Weiner. "NCI designation is important, because with it comes the national recognition for excellence and significant federal dollars needed to sustain the progress we've begun. Our researchers will be able to purchase the very latest equipment, our progress will attract other top researchers and clinicians from all over the world, and Louisiana's cancer patients will have immediate access to clinical trials they would otherwise have to travel out of state to participate in." Groundbreaking ceremony
Without the backing of an incredible network of supporters from both the public and private sector, this historic moment might never have taken place.

Directors Following a lengthy selection process, Hillier Architecture, a nationally recognized design and facilities planning firm with five offices across the country, has been chosen to design the new research building. This firm is uniquely qualified to address the laboratory, scientific and technological requirements for the project, as they have designed several cancer research buildings for other clients in the past. Representatives from Hillier participated recently in two planning retreats with Dr. Weiner and Dr. Oliver Sartor, co-director of the LCRC and director of LSU's Stanley S. Scott Cancer Center, as well as several of the other research scientists who will call the building home. "The purpose of the meetings was to understand the requirements of the researchers who will be working in the building as well as to bring our experience and expertise to the table," said Steve McDaniel, principal architect with Hillier. "Our priorities right now are to design a structure that will yield the maximum amount of research space, as well as promote interaction and optimal collaboration among the researchers from both Tulane and LSU." Other priorities identified at the planning retreats include highly accessible common areas for shared core equipment, creativity in bringing natural light into the building, and "shelled" space that will be outfitted with additional laboratories as the Consortium continues to grow. McDaniel added that Hillier has been charged with fulfilling the vision that this research building is a recruiting tool, a state-of-the art lure for attracting top-notch researchers from all over the world here to New Orleans. Hillier has selected the local architectural firm of Lyons & Hudson to work with them on this project.

The Consortium and its new Cancer Research Center is expected to fuel economic development for the city and the state, with a projected five-year financial impact of more than $350 million once the Center is fully operational. More importantly, it will help diversify the state's economy and provide jobs paying considerably more than the Louisiana average wage. It will also provide new career opportunities for graduates of Louisiana universities.
Roy S. Weiner, M.D., and Oliver Sartor, M.D., co-directors of the Louisiana Cancer Research Consortium


Sens. Hainkel, Boissiere, & Bajoie The Consortium was created during the Louisiana State Legislature's 2002 Special Session in a bill introduced by Senator John J. Hainkel, Jr., and is supported by three cents of a 12-cent increase in the tax on a pack of cigarettes introduced by then Rep. (now Lieutenant Governor) Mitch Landrieu during the 2002 Regular Legislative Session. The tax is expected to generate approximately $10 million per year and is dedicated to funding infrastructure and cancer research program development for the new Consortium. "The groundbreaking was a galvanizing event for all supporters of the Consortium," said Weiner, "and I am thrilled to be able to thank them and celebrate our progress in this way. But, I'll be even more thrilled when we gather again for the ribbon-cutting ceremony for the new Louisiana Cancer Research Center!"
Senator John J. Hainkel, Jr.; Senator Lambert Boissiere, Jr.; and Senator Diana Bajoie

Louisiana Cancer Research Center Groundbreaking Speakers:
Governor Kathleen Blanco
Lt. Governor Mitch Landrieu
Andy Kopplin, office of former Governor Mike Foster
Sen. John J. Hainkel, Jr.
Sen. Diana E. Bajoie
Sen. Lambert Boissiere, Jr.
Sen. Paulette R. Irons
Rep. Karen R. Carter
Mayor C. Ray Nagin
City Council President Oliver M. Thomas, Jr.
City Councilmember Jacquelyn B. Clarkson
City Councilmember Renee Gill Pratt
Roger H. Ogden, Chair, LSU System Board of Supervisors
Catherine D. Pierson, Chair, Board of Tulane
William L. Jenkins, D.V.M., Ph.D., President, LSU System
Walter C. Flower, III, Chair, Board of Governors, Tulane University Health Sciences Center
John A. Rock, M.D., Chancellor, LSU Health Sciences Center, New Orleans
Paul K. Whelton, M.D., M.Sc., Senior Vice President, Tulane University Health Sciences Center
Oliver Sartor, M.D., Director, Stanley S. Scott Cancer Center, LSU Health Sciences Center
Roy S. Weiner, M.D., Director, Tulane Cancer Center, Tulane University Health Sciences Center

------------
Meet Melanie Ehrlich
Tulane Cancer Research Pioneer
With the exception of the immune system and reproductive cells, the same DNA occurs in every cell in our bodies. What then, makes a skin cell act like a skin cell and not a muscle cell or a brain cell? The answer can be found in an area of science called epigenetics. It's an area in which Melanie Ehrlich, Ph.D., Professor of Biochemistry and Genetics, is a world-renowned expert. "Although the DNA is the same in both the skin and the muscle cells, there are processes that control which genes are turned on or expressed in each cell type and are transmitted from cell to progeny cell," said Ehrlich. "This difference in gene expression among different types of cells is what makes them look and behave differently."

To regulate the level at which any gene is expressed, regulatory proteins bind to certain parts of the DNA for each gene. There is a kind of "tag," called a methyl group, that can be attached to regulatory parts of genes not necessary for any given cell's function. The process of putting on this tag is called DNA methylation. The placement of the methyl tags on the DNA as well as on structural proteins that bind to the DNA can determine which genes are expressed and which are not. In short, the methyl tags help to make skin cells act like skin cells. "DNA methylation is essential for the normal development and functioning of an organism and is extraordinarily important in understanding the development of every type of human cancer," said Ehrlich. In fact, in 1983, Ehrlich's lab and the lab of Bert Vogelstein, from Johns Hopkins Medical School, independently and by different methods first reported changes in DNA methylation in human cancer cells. They pioneered this area of cancer research. "Now there are hundreds of papers published each year in this area," said Ehrlich. "It's currently one of the hottest topics in cancer research."

Ehrlich says that most research on DNA methylation and cancer involves abnormal increases in the placement of DNA methylation tags. If the genes affected by abnormal methylation tagging are involved in keeping cell proliferation in check, uncontrolled cell division can occur, and this uncontrolled cell growth is the main problem underlying cancer. Her lab is studying abnormal increases as well as abnormal decreases in methylation tagging and their relationship to cancer. "For the most part, cancer-causing DNA methylation changes occur as 'mistakes' cells make at some time after birth," said Ehrlich. "The longer the cells are around, the higher the chance for abnormal increases or decreases in DNA methylation. This may help to explain why cancer incidence is age-related."

A better understanding of abnormal DNA methylation can have very practical applications in cancer diagnosis and treatment. Scientists are trying to change the abnormal tags or the effects of these tags as one treatment for cancer and are hoping to use these tagging differences in early diagnosis as well as in monitoring various treatments. For instance, Dr. Ehrlich's lab recently discovered, in collaboration with Dr. Martin Widschwendter, a gynecologic oncologist from Innsbruck, Austria, that extensive losses of methylation from two types of highly repeated DNA sequences, called satellite DNA sequences, were the best indicators of poor prognosis in ovarian cancer. "There is also a type of cancer chemotherapy that involves trying to reverse abnormal increases in DNA methylation that shut down tumor suppressor genes," said Ehrlich. "This has had limited success." However, Ehrlich warns that research on losses of DNA methylation in cancer indicates the need for caution in these kinds of therapies, because an unwanted consequence of decreasing DNA methylation could be to increase metastasis.

Dr. Ehrlich is a graduate of Columbia University and the State University of New York at Stony Brook. She did her postdoctoral research at the Albert Einstein School of Medicine. She has been a faculty member at Tulane University Health Sciences Center since 1971 and is a member of the Molecular Genetics Program of the Louisiana Cancer Research Consortium. Dr. Ehrlich is founder, for nine years was president, and is currently a vice-president of the DNA Methylation Society, an international scientific society open to all those interested in aspects of biological methylation.

This figure illustrates Southern blotting analysis of some of the 120 ovarian tumors Dr. Ehrlich's lab studied for changes in methylation of a highly repeated DNA sequence (a satellite DNA). A hypomethylation score of 4 for the tumor means the most loss of normal methylation and a score of 0 means normal methylation in the tumor. The normal control tissues show no hypomethylation (hypomethylation score 0), while sperm, which normally has a very low level of methylation in this satellite DNA, has a hypomethylation score of 4 and serves as a hypomethylation standard. In this study of ovarian cancer patients followed for at least 4 years after optimal surgery, patients with hypomethylation scores of 3 or 4 in their tumor DNA tended to have a significantly worse prognosis than those with lower scores. Furthermore, a hypomethylation score of 2 or less was a better predictor of good recovery for ovarian cancer patients than conventional markers .
------------
Thanking the Benefactors who Support Our Mission
Ladies Auxiliary VFW
The Ladies Auxiliary VFW of Louisiana recently presented the Tulane Cancer Center with a check for $11,248.86 to be used for cancer research. "Each year, our organization provides a gift to an accredited hospital or cancer research center," said Lucy Frederick, 2002-2003 president. "We have once again chosen to make this monetary donation to the Tulane Cancer Center." Roy S. Weiner, M.D., was an invited guest at the group's recent joint opening session in Alexandria, Louisiana, where he was presented with their kind donation. "The Tulane Cancer Center couldn't ask for better friends," said Dr. Weiner. "This organization's steadfast commitment to our mission and vision over the years is vital to the continuation of our progress."

Cancer Crusaders
At their recent Survivor's Luncheon, the Cancer Crusaders presented both Dr. Roy Weiner and Dr. Oliver Sartor, director of LSU's Stanley S. Scott Cancer Center, with checks for $45,581.33, representing the results of their fundraising efforts for 2003. Cancer Crusaders is a non-profit, all volunteer organization founded in 1976 for the purpose of raising funds for cancer research in the New Orleans area. Proceeds raised by the organization are donated annually to the Tulane University and Louisiana State University medical schools in New Orleans for the express purpose of cancer research. Cancer Crusaders has raised in excess of $1,500,000 for cancer research over the years. "This organization's tireless effort on behalf of cancer research in Louisiana for the last 25 plus years is truly an inspiration to our entire community," said Dr. Weiner. "In fact, Cancer Crusaders has set a standard of community involvement and commitment to which we should all aspire."

Allemands - Paradis Lions Club
Tulane Cancer Center would like to thank Wilton and Geraldine Comardelle and the Allemands - Paradis Louisiana Lions Club for a $10,000 donation to establish a new Orthopedic Oncology Research Fund that will support important new research initiatives of Scott Wilson, M.D., Chief of Orthopedic Oncology. "Our Lions Club was chartered in 1955 and has contributed greatly to our community over the years," said Mr. Comardelle. "Although the club disbanded recently due to dropping membership, an anonymous member suggested we make this contribution to the Tulane Cancer Center in memory of a friend who passed away from cancer." "This gift is vital to continuing the momentum gained by Tulane researchers over the years in their fight against cancer and other diseases," said Dr. Weiner. "Thanks to the generosity of the Comardelles and other benefactors like them, significant progress is being made every day right here in Louisiana to understand these disease processes and hopefully one day find cures. On behalf of all the physician scientists and researchers who are members of the Tulane Cancer Center, I thank them for their wonderfully generous support."
Check presentation
Geraldine Comardelle (center) is pictured here with (from left) Roy S. Weiner, M.D.; Elly Zakris, M.D., Chief Of Radiation Oncology; R. Edward Newsome, M.D., Assistant Professor Of Plastic And Reconstructive Surgery; Scott Wilson, M.D., Chief of Orthopedic Oncology; and Wilton Comardelle.
------------
Research Day Winners 2004
Tulane Cancer Center Faculty/Labs Support Winners at 2004 Research Days Congratulations to the following winners at the Sixteenth Annual Tulane Health Sciences Center Research Days, held April 28-29, 2004, and their faculty advisors, who are members of the Tulane Cancer Center:
------------
A Message from the Director
Roy S. Weiner, M.D.
Director of the Tulane Cancer Center
This issue carries lots of good news and salutes our oncology nurses.

We have so much to boast about. Our groundbreaking symbolizes our commitment to work with LSU to build a quality cancer center for the citizens of the Gulf South. Our research accomplishments are tangible evidence that we are a creative and productive force in the national quest for knowledge of cancer, how to cure it and how to prevent it. Our dedicated faculty and staff who labor in the service of our patients are the people who translate the knowledge we have gained and the discoveries we have made into treatment options for the patients who turn to us.

Our oncology nurses are the frontline caregivers who provide treatment, counsel, solace, and support. Though their motivation, their mission, and their dedication share much in common, our oncology nurses have chosen different paths to fulfill their goals. Our clinic nurses are the constant support of our patients, who turn to "their nurse" for help in understanding their symptoms and their therapies. Our clinic nurses are accessible by phone, by e-mail, and in person to answer questions, solve problems and provide assistance. Two of our clinic nurses have achieved their certification in oncology nursing. Our treatment nurses provide care during infusion of chemotherapy or administration of radiation therapy. These nurses understand the treatments they are administering and explain to the patients the side effects and how to deal with them. Treatment nurses provide the teaching necessary to avoid unnecessary risks of complications. Our inpatient nurses are highly trained in the care of patients undergoing treatment. They coordinate the inpatient care experience and participate in the discharge planning for each patient. These nurses apply their skills and expertise to patients who require inpatient care for management of disease symptoms as well as side effects related to treatment. Their patients are frequently very sick and are grappling with emotional stress as well as physical pain. Inpatient nurses act as our patients' caregivers, guides, and supporters during their inpatient stay.

The oncology research nurses all have clinic or treatment experience in the inpatient or outpatient setting. They have chosen to undertake the tasks of identifying appropriate patients for our research protocols, teaching those patients about clinical research in general and the studies appropriate for them in particular, and guiding the patients through their research therapy to assure their safety and compliance. Betty Jurisich is the director of the Office of Clinical Research. She leads a group of nine, including four oncology research nurses. In addition to being an oncology-certified nurse, Betty has a masters degree in health administration and a special interest in cancer prevention. Of critical importance to the proper conduct of clinical research is the compliance officer.

Sandra Robertson, D.V.M., is our compliance officer who oversees the regulatory affairs of our 88 active protocols and assures that each study has up-to-date toxicity information and current approval from our Institutional Review Board. Her job requires diligence and comfort with medical and scientific issues. We are fortunate to have Sandy's expertise and her background in veterinary medicine. The cost of conducting clinical research has escalated dramatically over the past decade. The mandated regulatory work has been the principal driver of cost. Reimbursements do not cover our expenses for clinical research. Therefore, in order to offer our patients access to clinical trials, we subsidize our Office of Clinical Research from philanthropic funds. The finances are complex, and we depend on Keadren Green, our expert business manager, who brings years of experience and a masters degree in health administration to her job.

In this issue, you will read about Tulane's Affiliated Community Clinical Trials Integrated Oncology Network -- or ACCTION -- which makes our clinical research protocols available to patients from Pensacola to Houma and as far north as Alexandria without their having to travel to New Orleans to participate. All patients who participate in clinical trials through ACCTION maintain their relationships with their specialists who care for them close to home. We have a proud record of accomplishment in clinical research, but we have not achieved our patient participation goal. As a nation, we need 1 out of every 5 cancer patients to participate in a clinical trial in order to test the new options for treatment and to determine which are best for each person presenting with cancer. Nationally, only one in 25 patients participate in clinical trials. In Louisiana, only 1 in 50 patients participates in a clinical trial. Not only are patients missing out on improving their own chances for cure by not participating, but they are slowing the progress that can help all patients with cancer. Our goals are to make clinical trials readily accessible and to teach both patients and their doctors the value of participating. We need progress in treatment; we must work hard to gain that progress in partnership with our patients and our community colleagues.
------------
Inside the Tulane Cancer Center is a quarterly publication of the Tulane Cancer Center, Tulane University Health Sciences Center, New Orleans.
Executive Editor: Roy S. Weiner, M.D., Editor: Melanie N. Cross, Art Director: Kathy O. Barbazon

Address inquiries regarding this newsletter to: Melanie N. Cross
(504) 988-6592, fax (504) 988-6077, mcross@tulane.edu

To inquire about cancer research and treatment programs at Tulane
please call one of these toll-free numbers:
(800) 588-5300 (Physicians) 24 hours a day
(800) 588-5800 (Patients and others) 8:00 am to 8:00 pm US Central Time
Tulane University Hospital & Clinic (http://www.tulanehospital.com)

Tulane Cancer Center
http://www.som.tulane.edu/cancer or http://www.canceriscurable.com
Box SL-68, 1430 Tulane Ave., New Orleans, Louisiana 70122-2699
(504) 988-6060, fax (504) 988-6077
------------
This page is http://www.som.tulane.edu/cancer/newsletter0604.html
This page was last updated on
Return to the top of this page.
Return to the Tulane Cancer Center homepage.

Calendars Clinical Trials Faculty Links Location News

Search Site index